Skip to main content
SpringerLink
Log in

Early detection and aggressive treatment of prostate cancer

Groping in the dark

  • Editorials
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fowler FJ, Bin L, Collins MM, et al. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med. 1998;104:526–32.

    Article  PubMed  Google Scholar 

  2. Woloshin S, Schwartz L. The U.S. Postal Service and cancer screening-stamps of approval? N Engl J Med. 1999;340:884–7.

    Article  PubMed  CAS  Google Scholar 

  3. Tarone R, Chu K, Brawley O. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000;11:167–70.

    Article  PubMed  CAS  Google Scholar 

  4. Bartsch G, Horninger W, Klocker H, et al. Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyrol, Austria. J Urol. 2000; 163:88.

    Google Scholar 

  5. Brawley O. Prostate carcinoma incidence and patient mortality. The effects of screening and early detection. Cancer. 1997;80: 1857–63.

    Article  PubMed  CAS  Google Scholar 

  6. Etzioni R, Legler J, Feuer E, Merrill R, Cronin I, Hankey B. Cancer surveillance series: interpreting trends in prostate cancer-Part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst. 1999;91:1033–9.

    Article  PubMed  CAS  Google Scholar 

  7. U.S. Preventive Services Task Force. Screening for cervical cancer. In: U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed. Baltimore, Md: Williams and Wilkins; 1996:105–18.

    Google Scholar 

  8. Fowler F, Collins MM, Albertsen P, Zietman A, Elliott D, Barry M. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA. 2000;283:3217–22.

    Article  PubMed  Google Scholar 

  9. Catalona W, Ramos C, Carvalhal G, Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology. 2000;55:791–5.

    Article  PubMed  CAS  Google Scholar 

  10. Carter H. A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: the only rational approach for men 50 years old and older. Urology. 2000;55:796–9.

    Article  PubMed  CAS  Google Scholar 

  11. Babian R. Extended field prostate biopsy enhances cancer detection. Urology. 2000;55:453–6.

    Article  Google Scholar 

  12. Terris M. Extended field prostate biopsies: too much of a good thing? Urology. 2000;55:456–60.

    Article  Google Scholar 

  13. Catalona WJ, Richie JP, Ahmann FR. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283–90.

    PubMed  CAS  Google Scholar 

  14. Schroder FH, van der Cruisjen-Koeter I, de Koning HJ, Vis AN, Hoedemaker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol. 2000;163:806–12.

    Article  PubMed  CAS  Google Scholar 

  15. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997;277:1452–5.

    Article  PubMed  CAS  Google Scholar 

  16. Babaian R, Ayala A, Bhadkamkar V, Naccarato W, Fritsche H. The incidence of prostate cancer in the PSA reflex range of 2.5 and 4.0 ng/mL. J Urol. 2000;163:88.

    Article  Google Scholar 

  17. Djavan B, Zlotta A, Remzi M. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol. 2000;163:1144–9.

    Article  PubMed  CAS  Google Scholar 

  18. Lu-Yao G, Yao S-L. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997;349:906–10.

    Article  PubMed  CAS  Google Scholar 

  19. Fowler FJ, Roman A, Barry MJ, Wasson J, Lu-Yao G, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The national Medicare experience; 1988–1990. Urology. 1993;42:622–9.

    Article  PubMed  Google Scholar 

  20. Kattan M, Cowen M, Miles B. A decisiion analysis for treatment of clinically localized prostate cancer. J Gen Intern Med. 1997;12:299–305.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Massachusetts General Hospital, Boston, Mass

    Michael J. Barry MD

Authors
  1. Michael J. Barry MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barry, M.J. Early detection and aggressive treatment of prostate cancer. J GEN INTERN MED 15, 749–751 (2000). https://doi.org/10.1046/j.1525-1497.2000.00816.x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1046/j.1525-1497.2000.00816.x

Search

Navigation